LiDCO Group plc : Exercise of Share Options

LiDCO Group Plc

("LiDCO" or the "Company")

Exercise of Share Options

LiDCO Group Plc (AIM: LID), the cardiovascular monitoring company, announces that following the exercise of share options under the Company's EMI Scheme, application has been made for 35,000 new ordinary shares of 0.5 pence each ("Ordinary Shares") to be admitted to trading on AIM, which will rank pari passu with the Company's existing Ordinary Shares, and admission to trading is expected to be effective on 23 October 2013 ("Admission").

Following Admission of the new Ordinary Shares, the Company will have 193,870,304 Ordinary Shares in issue with each share carrying the right to one vote. No Ordinary Shares are held in Treasury. The total number of voting rights in LiDCO is therefore 193,870,304. This number may be used by shareholders as the denominator for the calculation by which they may determine if they are required to notify their interest in, or a change to their interest in, LiDCO under the Disclosure and Transparency Rules.

For further information, please contact:

About LiDCO Group Plc (www.lidco.com)

LiDCO is a supplier of non-invasive and minimally invasive hemodynamic equipment to hospitals used to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre.

Increasingly clinical studies are showing that the optimisation of patients' hemodynamic status in high risk patients produces better outcomes and reduced hospital stay.  LiDCO's computer-based technology, developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.

Key Products:

LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%).

LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anaesthetists to receive accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery.  The LiDCOrapidprovides:

·    early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug

·    quantification of hemodynamic response

·    guidance on effective delivery of fluids to ensure the right amount at the right time

LiDCOview: an easy-to-use graphical display of historical LiDCOplusand LiDCOrapidhemodynamic data.

LiDCO Unity Software: software incorporated into LiDCOrapidv2 that allows the LiDCOrapidmonitor to co-display Covidien's level of consciousness parameter ('BISTM')*and add the convenience of CNSystem's continuous non-invasive blood pressure monitoring ('CNAP')**. This will address a growing requirement for non-invasive monitoring solutions that are more comprehensive and can effectively replace multiple single parameter monitors.

*BISTMand Bispectral Index are trademarks of Covidien LP registered in the US and foreign countries.

* CNAPTM is a trademark of CNSystems Medizintechnik AG.

LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream. 

LiDCO Distribution Network:

LiDCO sells directly to hospitals in the UK and USAand through a network of specialty critical care and anaesthesia distributors in the rest of the world.

LiDCO's marketing office is in Cambridge, its manufacturing facility and headquarters are in London and its shares are traded on AIM.